These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 17306791

  • 21. Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques.
    He L, Game BA, Nareika A, Garvey WT, Huang Y.
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):212-22. PubMed ID: 17110803
    [Abstract] [Full Text] [Related]

  • 22. Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Matthijsen RA, de Winther MP, Kuipers D, van der Made I, Weber C, Herias MV, Gijbels MJ, Buurman WA.
    Circulation; 2009 Apr 28; 119(16):2188-95. PubMed ID: 19380618
    [Abstract] [Full Text] [Related]

  • 23. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice.
    Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K, Hayashi Y.
    Cardiovasc Res; 2009 May 01; 82(2):371-81. PubMed ID: 19176597
    [Abstract] [Full Text] [Related]

  • 24. Specific loss of toll-like receptor 2 on bone marrow derived cells decreases atherosclerosis in LDL receptor null mice.
    Hasu M, Thabet M, Tam N, Whitman SC.
    Can J Physiol Pharmacol; 2011 Oct 01; 89(10):737-42. PubMed ID: 21895526
    [Abstract] [Full Text] [Related]

  • 25. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis.
    Ishigaki Y, Katagiri H, Gao J, Yamada T, Imai J, Uno K, Hasegawa Y, Kaneko K, Ogihara T, Ishihara H, Sato Y, Takikawa K, Nishimichi N, Matsuda H, Sawamura T, Oka Y.
    Circulation; 2008 Jul 01; 118(1):75-83. PubMed ID: 18559699
    [Abstract] [Full Text] [Related]

  • 26. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice.
    Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, Chatenoud L, Mach F.
    Circulation; 2006 Oct 31; 114(18):1977-84. PubMed ID: 17043169
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.
    Kolh P, Rolin S, Tchana-Sato V, Pétein M, Ghuysen A, Lambermont B, Hanson J, Magis D, Segers P, Masereel B, D'Orio V, Dogne JM.
    Prostaglandins Other Lipid Mediat; 2006 Mar 31; 79(1-2):53-73. PubMed ID: 16516810
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Enhanced expression of salusin-β contributes to progression of atherosclerosis in LDL receptor deficient mice.
    Zhou CH, Liu LL, Wu YQ, Song Z, Xing SH.
    Can J Physiol Pharmacol; 2012 Apr 31; 90(4):463-71. PubMed ID: 22462492
    [Abstract] [Full Text] [Related]

  • 32. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.
    Zuccollo A, Shi C, Mastroianni R, Maitland-Toolan KA, Weisbrod RM, Zang M, Xu S, Jiang B, Oliver-Krasinski JM, Cayatte AJ, Corda S, Lavielle G, Verbeuren TJ, Cohen RA.
    Circulation; 2005 Nov 08; 112(19):3001-8. PubMed ID: 16260636
    [Abstract] [Full Text] [Related]

  • 33. Lack of phosphatidylethanolamine N-methyltransferase alters plasma VLDL phospholipids and attenuates atherosclerosis in mice.
    Zhao Y, Su B, Jacobs RL, Kennedy B, Francis GA, Waddington E, Brosnan JT, Vance JE, Vance DE.
    Arterioscler Thromb Vasc Biol; 2009 Sep 08; 29(9):1349-55. PubMed ID: 19520976
    [Abstract] [Full Text] [Related]

  • 34. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet.
    Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, Satoh H, Inoue K, Kawase Y, Jishage K, Suzuki H, Takeya M, Schnackenberg L, Beger R, Hermonat PL, Thomas M, Sawamura T.
    Circ Res; 2007 Jun 08; 100(11):1634-42. PubMed ID: 17478727
    [Abstract] [Full Text] [Related]

  • 35. Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice.
    Shiraishi Y, Watanabe T, Suguro T, Nagashima M, Kato R, Hongo S, Itabe H, Miyazaki A, Hirano T, Adachi M.
    J Hypertens; 2008 Oct 08; 26(10):1955-65. PubMed ID: 18806619
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice.
    Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F.
    Arterioscler Thromb Vasc Biol; 2008 Jun 08; 28(6):1090-6. PubMed ID: 18388327
    [Abstract] [Full Text] [Related]

  • 38. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice.
    Jawien J, Gajda M, Wołkow P, Zurańska J, Olszanecki R, Korbut R.
    J Physiol Pharmacol; 2008 Sep 08; 59(3):633-9. PubMed ID: 18953103
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Chronic exposure to schistosome eggs reduces serum cholesterol but has no effect on atherosclerotic lesion development.
    La Flamme AC, Harvie M, Kenwright D, Cameron K, Rawlence N, Low YS, McKenzie S.
    Parasite Immunol; 2007 May 08; 29(5):259-66. PubMed ID: 17430549
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.